ABSTRACT: Marked interindividual variation exists in blood pressure response to benazepril, which is considered to have genetic basis. Our objectives were to evaluate whether the E112D polymorphism in the prolylcarboxypeptidase (PRCP) gene has impact on blood pressure response to benazepril.
Hypertensive patients from Huoqiu County and Yuexi County of Anhui Province received daily treatment with an oral dosage of 10 mg benazepril for 15 days. Genotypes of the E112D polymorphism in the PRCP gene were determined by TaqMan SNP genotyping assay. Multivariate linear and Logistic regressions using generalized estimating equation model were performed in a total of 1092 patients to evaluate the association of PRCP genotypes and blood pressure response to benazepril.
Patients carrying ED or DD genotype had a less systolic blood pressure reduction (adjusted beta = -3.7 + or - 1.1, P < 0.001), a less diastolic blood pressure reduction (adjusted beta = -3.1 + or - 0.8, P < 0.001) and a lower percentage of reaching target blood pressure defined as SBP lower than 140 mmHg and DBP lower than 90 mmHg (adjusted OR = 0.6, P = 0.005) than those patients carrying EE genotype. In addition, the results from stratified analysis by county (Huoqiu or Yuexi) were similar to those observed in the pooled population.
Our data suggest that the E112D polymorphism in the PRCP gene may be a useful genetic marker to predict the antihypertensive effect of short-term benazepril treatment in hypertensive patients of Anhui Province, China.
Chinese medical journal 10/2009; 122(20):2461-5. · 0.86 Impact Factor
ABSTRACT: To explore the distribution of bone mineral density (BMD) with age and to depict independent effects of age, year since menopause, height and weight on BMD and then to develop predictive model based on such determinants.
3008 pair of female twins were enrolled and their sociodemographic and envionmental data were collected with a standard questionnaire. Dual-energy X ray absorptionmetry (DPX) was used to measure subjects' BMD of all bones. Statistic analysis were done by applying SAS 6.12 and SPLUS software.
The outcome variables studied here included BMDs of second to forth lumbar spine, total spine, femoral neck, wards' triangle, trochanter, arm and total body. Our results showed that BMDs of all sites changed with age similarly, but both the age when peak bone mass reached and the bone mass loss varied among different site. Those made of trabecular mainly reached peak bone mass earlier and began to bone mass loss earlier, and the loss rates were higher. BMD values was affected by age, years since menopause, height and weight, but the independent effect of each variables was nonlinear over the whole age range studied here; All subjects were classfied into three groups according to their age, and predictive models for each bone site were developed. These models were tested and found that the predictive values of bone mass density, obtained by these predictive model, were similar to their actual values.
Our result showed that BMD values can be predicted by some easily measure variables based on the predictive models provided in this study, which provides a simple method to diagnose Osteoporosis for rural female.
Wei sheng yan jiu = Journal of hygiene research 06/2006; 35(3):326-9.
ABSTRACT: Inflammation is a major cause of restenosis after coronary stenting. Intercellular adhesion molecule-1 (ICAM-1) is an important adhesion molecule that plays a key role in the tight adhesion between leukocytes and vascular endothelium. The object of this study was to investigate the association between the K469E polymorphism of the ICAM-1 gene and restenosis after coronary stenting in North Chinese population.
The ICAM-1 K469E polymorphism was genotyped using polymerase chain reaction-restriction fragment length polymorphism method in 124 patients who had undergone coronary stenting and coronary angiography at least 3 months earlier. Information on clinical risk factors and procedure-related data were also collected.
Of 124 enrolled patients in total, there were 72 cases of in-stent restenosis. The restenosis rate in this population was 58.1%. The frequencies of the three possible genotypes of the ICAM-1 K469E polymorphism were: KK genotype 50.8%, EE genotype 41.9%, and EK genotype 41.9%. Among restenosis patients, the frequency of the KK genotype was 58.3% and the frequency of E allele carriers was 41.7%. Among non-restenosis patients, the frequency of the KK genotype was 40.4%, and the frequency of E allele carriers was 59.6%. The distribution of these two genotype groups between restenosis and non-restenosis patients was significantly different (P = 0.049). Using multivariate logistic regression, the difference between the two groups was more apparent. The odds ratio of KK homozygotes vs E allele carriers was 2.6, with 95% confidence interval 1.2 - 5.8 (P = 0.018). After grading of risk factors, we found that the KK genotype was a stronger predictor of in-stent restenosis in obesity or hyperlipemia patients, with an odds ratio of 9.3 and 3.7, respectively (P < 0.05).
In our study population, KK homozygotes of the ICAM-1 codon 469 mutation had a higher risk of restenosis after coronary stenting, especially in the case of obese or hyperlipemia patients.
Chinese medical journal 03/2004; 117(2):172-5. · 0.86 Impact Factor